| 2026-08-11 | Press release | NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth |
| 2026-08-04 | Press release | NeurAxis Expands Payer Coverage with New Policies |
| 2026-07-28 | Press release | NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 |
| 2026-05-12 | Press release | NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth |
| 2026-05-05 | Press release | NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 |
| 2026-04-22 | Press release | NeurAxis Expands Payer Coverage with Four New Medical Policies |
| 2026-04-10 | Press release | NeurAxis, Inc. Announces Preferred Stock Dividend |
| 2026-03-19 | Press release | NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-12 | Press release | NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026 |
| 2026-01-08 | Press release | NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimburseme |
| 2025-12-19 | Press release | NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Liv |
| 2025-12-01 | Press release | NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional A |
| 2025-11-12 | Press release | NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives |
| 2025-11-11 | Press release | NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues |
| 2025-11-04 | Press release | NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025 |
| 2025-10-24 | Press release | NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea |
| 2025-09-18 | Press release | NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 |
| 2025-08-12 | Press release | NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues |
| 2025-08-05 | Press release | NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025 |
| 2025-06-17 | Press release | NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives |
| 2025-06-10 | Press release | NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional |
| 2025-05-22 | Press release | NeurAxis Announces Closing of $5.0 Million Registered Direct Offering |
| 2025-05-21 | Press release | NeurAxis Announces $5.0 Million Registered Direct Offering |
| 2025-05-20 | Press release | NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Na |
| 2025-05-12 | Press release | NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues |
| 2025-05-05 | Press release | NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 |
| 2025-04-15 | Press release | NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 |
| 2025-03-20 | Press release | NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues |
| 2025-03-12 | Press release | NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025 |
| 2025-01-21 | Press release | UPDATE – NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Acros |
| 2025-01-21 | Press release | NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States |
| 2025-01-13 | Press release | NeurAxis Inc. Issues Letter to Shareholders |
| 2025-01-08 | Press release | NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year |
| 2025-01-06 | Press release | NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
| 2024-12-10 | Press release | NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation |
| 2024-11-12 | Press release | NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues |
| 2024-11-05 | Press release | NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 |
| 2024-11-04 | Press release | NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market |
| 2024-10-29 | Press release | NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 |
| 2024-10-22 | Press release | NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation |